THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease (DeCOG)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01355120|
Recruitment Status : Completed
First Posted : May 17, 2011
Last Update Posted : June 23, 2014
This is an open-label, multi-center, single-arm clinical phase II study to further characterize the efficacy and safety of ipilimumab in patients with or without systemic pretreatment metastatic ocular melanoma.
The DeCOG-MM-PAL11-Trial will be continued only for patients with ocular melanoma because sufficient numbers of cutaneous and mucosal melanoma patients have already been recruited. In order to allow the separate subgroup analysis as planned in the protocol for ocular melanoma it is mandatory to focus the recruitment to this patient population. Only this will guarantee a valid evaluation of all cohorts. Ocular melanoma is defined as melanomas originated from uvea, the choroid, the ciliary body and conjunctiva. (see McCartney ACE "Pathology of ocular melanomas" British Medical Bulltta, 1995, Vol 51, No 3 pp 678-693) The same criteria and treatment procedure as those used before will be applied for the patients with advanced ocular melanoma. Since no treatment standard in those patients does exist, also patients without prior systemic treatment can be included in this study. Therefore, the 5th inclusion criterion has been adapted in order to enrol the eligible patients.
|Condition or disease||Intervention/treatment||Phase|
|Ocular Melanoma||Drug: Ipilimumab||Phase 2|
Treatment with the anti-CTLA-4 mAb Ipilimumab monotherapy of each patient in the scope of this trial is defined as induction plus re-induction of eligible patients until 12 months after first receipt of study medication
Ipilimumab will be applied to melanoma patients according to the protocol of the completed Medarex study MDX-010-20: Ipilimumab by IV infusion, 3 mg/kg, day 1 (Week 1), 22 (Week 4), 43 (Week 7), 64 (Week 10)
Patients who progress following stable disease of ≥ 3 months duration starting from diagnosis at week 12 tumor assessment or patients who have progressed following an initial response (partial or complete) assessed at week 12 may be offered additional cycles of therapy with the originally assigned treatment regimen until off-treatment criteria are met, provided they meet re-treatment eligibility requirements. No patient will be re-treated if they experience a Grade 3 or higher gastrointestinal or certain other immune-related adverse events (irAE) (refer to section 5.2 and 5.3). No patient with disease progression following the first cycle of study medication will be permitted to be re-treated with study medication.
The disease will be assessed at baseline, after 12 weeks and for patients with stable disease or better responses, thereafter every 12 weeks in the absence of PD with a maximum of one year. Response evaluation will be done according to immune-related response criteria (Wolchok et al., CCR 2009).
All patients who prematurely discontinued treatment due to a drug-related adverse event prior to Week 12 (in the absence of disease progression) will return for all study visits and procedures including Week 12 and, if appropriate, further re-staging assessments. Any patient with documented progression at any scheduled re-staging visit and who will not receive any re-induction will undergo no further re-staging visits.
Survival will be assessed every 3 months after the final dose of Ipilimumab until the end of the follow-up phase for the individual patient. FU phase for each subject is 1 year following first treatment dose. End of study will be at recruitment finished plus 1 year post start of treatment of last patient thus ensuring that 1 year survival rate can be estimated.
End of study is 1 year post LPFV. Recruiting period for the ocular melanoma:
Period of recruiting 12-18 months Enrolment start date (FPI): QIII 2011 Enrolment finish date (LPI): QI 2013 End of study: QI 2014
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||171 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||THE IPI - Multibasket Trial in Advanced Melanoma: Prospective Clinical Phase II Multibasket Study in Melanoma Patients With Advanced Disease (DeCOG MM-PAL11)|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2013|
Experimental: a human immunoglobulin
Four infusions (i.v.) of 3mg/kg Ipilimumab in week 1, week 4, week 7 and week 10
Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
Other Name: Yervoy
- Overall survival [ Time Frame: alive 12 months after date from the first study drug adminstration ]Overall survival rate at 12 months defined as the rate of patients alive 12 months after the date from the first study treatment for complete study
- safety and efficacy parameters [ Time Frame: 12 months after date from the first study drug adminstration ]The primary endpoint is the one-year survival rate. It is defined as the proportion of patients being alive 12 months after their first administration of the study treatment (ipilimumab).
- Efficacy according to immune-related response criteria (ir-RC) at any time during treatment [ Time Frame: 12 months after date from the first study drug administration ]
- Efficacy according RECIST criteria [ Time Frame: 12 months after date from the first study drug administration ]
- Progression free survival rate at 6 months [ Time Frame: 6 months after date from the first study drug administration ]
- Overall survival at 1 year in the subgroups (cutaneous, uveal, mucosal) [ Time Frame: 12 months after date from the first study drug administration ]
- To explore clinical efficacy of ipilimumab in relation to b-raf mutation status, brain metastases, LDH, HLA-A2 status [ Time Frame: 12 months after date from the first study drug administration ]
- To examine the value of peripheral blood absolute lymphocyte count (ALC) as a predictive biomarker in various patient cohorts with unresectable stage III-IV melanoma treated with ipilimumab monotherapy [ Time Frame: 12 weeks after date from the first study drug administration ]
- To evaluate possible surrogate markers in peripheral blood and tumour biopsy (translational research program) [ Time Frame: 12 weeks after date from the first study drug administration ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01355120
|Principal Investigator:||Dirk Schadendorf, Professor||University Hospital, Essen|